Brain and other Nervous System Cancers
- Brain and Nervous System, PediatricsA Phase 2 Study of Dabrafenib (NSC# 763760) With Trametinib (NSC# 763093) After Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)Principal Investigator: Nina Kadan-Lottick
- Brain and Nervous SystemA Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study of AG-881 in Subjects With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 MutationPrincipal Investigator: Antonio Omuro
- Brain and Nervous SystemGBM AGILE: Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens In Newly Diagnosed and Recurrent GBMPrincipal Investigator: Nicholas Blondin
- Brain and Nervous SystemPhase 1: BGB-290 in combination with TMZ in patients w/ IDH1/2-mutant WHO grade II-IV recurrent glioma: Phase 2: Grade II-III patients in will be stratified into 2 arms based on the timing of prior alkylator chemotherapy exposure; a third arm will include the subset of glioblastoma (grade IV) patientsPrincipal Investigator: Antonio Omuro
- Unknown Sites, Breast, Cervix, Urinary Bladder, Anus, Bones and Joints, Brain and Nervous System, Colon, Corpus Uteri, Esophagus, Eye and Orbit, Kidney, Larynx, Lip, Oral Cavity and Pharynx, Liver, Lung, Melanoma, skin, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Pancreas, Prostate, Rectum, Small Intestine, Soft Tissue, Stomach, Thyroid, Other Hematopoietic, Phase I, PediatricsA Phase 1a/1b Study of LY3405105 Administered to Patients with Advanced Solid TumorsPrincipal Investigator: Patricia LoRusso